N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite
Cellulite
Primary: Number of Aesthetic Improved Thighs of Responders According to Global Aesthetic Improvement Scale (GAIS) as Assessed Live by Treating Investigator at Month 9 — 23; 4; 1…
Phase 1 N=18 A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
Moderate Renal Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616 — 453; 369 hour*nmol/Liter
N/A N=66 Shared Decision Making Aid for Prosthetic Design
Amputation · Prosthesis User
Primary: Number of Participants Who Participated in and Completed 1 Hour Qualitative Interview Data Collection Via a Semi Structured Interview Guides — 38; 17; 11 Participants
Phase 2 N=139 A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Diabetic Retinopathy
Primary: Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36…
N/A N=76 Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
Multiple Sclerosis
Primary: Number of Participants Off Drug That Have New Inflammatory Disease Compared to Those on Drug. — 2; 1 Participants — p=0.124
N/A N=40 Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation
Overweight and Obesity · PreDiabetes · Insulin Resistance
Primary: Feasibility of CGM Use to Determine Type 2 Diabetes Risk — 33; 5 Participants
N/A N=50 Levita Magnetic Grasper Device Safety and Performance Study
Benign Gallbladder Disease
Primary: Safety Assessment of AEs — 50; 0 Participants
Phase 2 N=128 Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years
Phase 1 N=29 Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
Alzheimer's Disease
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 8; 5; 1 Participants
N/A N=32 Women's Health Communication Study
Gynecologic Cancer
Primary: Feasibility - Enrollment — 32 Participants
Phase 2 N=69 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Prostate Cancer
Primary: Disease Control Status — 4; 3; 0; 0 Participants
Phase 2 N=102 Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
Non-small Cell Lung Cancer
Primary: Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs) — 5; 5; 10 Participants
Phase 3 N=544 This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Hidradenitis Suppurativa
Primary: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) — 45.0; 41.8; 33.7 Percentage of participants — p=0.0070
Phase 2 N=18 A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants